Covalon Technologies Ltd. (OTCMKTS:CVALF) Short Interest Down 92.3% in December

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 100 shares, a decrease of 92.3% from the December 15th total of 1,300 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.0 days.

Covalon Technologies Stock Performance

CVALF traded down $0.09 during mid-day trading on Tuesday, reaching $2.12. The stock had a trading volume of 7,466 shares, compared to its average volume of 23,100. The stock has a market capitalization of $58.02 million, a P/E ratio of -70.56 and a beta of -0.27. The firm’s fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $2.20. Covalon Technologies has a 52 week low of $0.74 and a 52 week high of $3.08.

Covalon Technologies (OTCMKTS:CVALF) last announced its quarterly earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a negative return on equity of 4.40% and a negative net margin of 2.94%.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.